JULY 2013 Summary of Changes to the Queensland Health List of Approved Medicines (LAM)
as recommended by the Queensland Health Medicines Advisory Committee (QHMAC)
ITEM
#
13/061
13/057
MEDICINE
DUTASTERIDE
WITH
TAMSULOSIN
CAPSULE
500microgram
with
400microgram
IVABRADINE
TABLET 5mg
DECISION &
DATE
EFFECTIVE
ADDED
01-Oct-13
Urologists for use as per the PBS indications
ADDED
01-Oct-13
Cardiologists and Radiologists to reduce heart rate in patients in sinus rhythm undergoing CT coronary
angiography who do not respond to maximal doses of betablockers or are unable to tolerate beta blockers (or
when a beta-blocker is contraindicated).
Specialist Staff for
(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications;
(b) For use in postoperative nausea and vomiting (PONV) (i) in adult patients not responsive to alternative oral
antiemetic therapy and who cannot use other forms of ondansetron; and (ii) in children
(c) Use within Emergency Departments for acute gastroenteritis in children up to age sixteen years when
frequent vomiting is interfering with oral rehydration therapy. It is recommended that the Royal Children's
Hospital (Brisbane) Emergency Department Flowchart for Management of Acute Gastroenteritis be consulted
and followed.
Where medicines are used outside their TGA approved indications, patients should be made fully aware of the
status of the medicine and appropriate consent obtained.
Specialist Staff for patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
13/T01
ONDANSETRON
ORAL
DISINTEGRATING
TABLET 4mg
ADDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
13/T01
ONDANSETRON
ORAL
DISINTEGRATING
TABLET 8mg
13/058
PRASUGREL
TABLET 5mg,
10mg
ADDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
ADDED
01-Oct-13
13/062
PROGESTERONE
PESSARY 200mg
RESTRICTION
ADDED
01-Oct-13
Cardiologists in PCI capable hospitals as per the PBS indications
Specialist Obstetricians for women in preterm labour with shortened cervix and those with short cervices in
singleton pregnancies.
Where medicines are used outside their TGA approved indications, patients should be made fully aware of the
status of the medicine and appropriate consent obtained.
ITEM
#
MEDICINE
13/053
PROSTAGLANDIN
13/076
F2 ALPHA
(DINOPROST)
INJECTION
5mg in 1mL
(Prostin F2 alpha)
APIXABAN Tablet
2.5mg
DECISION &
DATE
EFFECTIVE
ADDED
01-Oct-13
AMENDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
AMENDED
01-Oct-13
13/055
A
BCG VACCINE,
DRIED LIVING
Injection 1.5mg
13/056
CLOPIDOGREL
TABLET 75mg
AMENDED
01-Oct-13
13/055
B
CYCLOSERINE
Capsule 250mg
AMENDED
01-Oct-13
13/T01
GRANISETRON
INJECTION 3mg
in 3mL
AMENDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
RESTRICTION
Specialist Obstetricians and Gynaecologists and Rural Generalist General Practitioners with an Advanced Skill in
Obstetrics and Gynaecology, for second line management of severe life-threatening primary postpartum
haemorrhage within the guidance of the Queensland Maternal and Neonatal Clinical Guideline “Primary
Postpartum Haemorrhage”. Where medicines are used outside their TGA approved indications, patients should
be made fully aware of the status of the medicine and, where appropriate informed consent cannot be obtained,
full details should be recorded in the patient chart.
For orthopaedic prophylaxis of venous thromboembolism in total hip and knee replacement.
For vaccination after approval by the Medical Advisor Tuberculosis, CHRISP and TB Control, Communicable
Diseases Unit or delegate OR Director Regional Tuberculosis Control Unit.
The Medical Advisor Tuberculosis, CHRISP and TB Control should be contacted for any multi-drug or extremely
drug resistant cases and can be contacted during business hours via (07) 3328 9755 or email at:
CHRISP_TB@health.qld.gov.au
Contact information for Regional TB Control Units is available at:
www.health.qld.gov.au/chrisp/tuberculosis/appointments.asp
Specialist Staff for use as per the PBS indications; and for use in patients undergoing arterial stenting for up to a
maximum of three months.
For treatment after approval by the Medical Advisor Tuberculosis, CHRISP and TB Control, Communicable
Diseases Unit or delegate OR Director Regional Tuberculosis Control Unit.
The Medical Advisor Tuberculosis, CHRISP and TB Control should be contacted for any multi-drug or extremely
drug resistant cases and can be contacted during business hours via (07) 3328 9755 or email at:
CHRISP_TB@health.qld.gov.au Contact information for Regional TB Control Units is available at:
www.health.qld.gov.au/chrisp/tuberculosis/appointments.asp
Specialist Staff for patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
Page 2 of 6
ITEM
#
MEDICINE
13/055
E
MOXIFLOXACIN
Solution for IV
infusion 400mg in
250mL;
Tablet 400mg
13/T01
ONDANSETRON
INJECTION 4mg
in 2mL
13/T01
ONDANSETRON
INJECTION 8mg
in 4mL
13/T01
ONDANSETRON
SYRUP 4mg in
5mL 50mL
13/T01
ONDANSETRON
TABLET 4mg
DECISION &
DATE
EFFECTIVE
AMENDED
01-Oct-13
AMENDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
AMENDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
AMENDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
AMENDED
01-Sep-13
(to be
reflected in
RESTRICTION
For use after approval by an Infectious diseases Physician or a Clinical Microbiologist or in accord with an
Infectious Diseases approved protocol:
(a) For empirical therapy of patients with community acquired pneumonia or acute bacterial meningitis who have
immediate hypersensitivity to penicillin and cannot be given cephalosporin;
b) For patients with an infection caused by an organism with proven resistance to antibiotic agents apart from
moxifloxacin, or who have severe allergy to standard agents where moxifloxacin is the most appropriate therapy
available;
OR
For treatment after approval by the Medical Advisor Tuberculosis, CHRISP and TB Control, Communicable
Diseases Unit or delegate OR Director Regional Tuberculosis Control Unit.
The Medical Advisor Tuberculosis, CHRISP and TB Control should be contacted for any multi-drug or extremely
drug resistant cases and can be contacted during business hours via (07) 3328 9755 or email at:
CHRISP_TB@health.qld.gov.au
Contact information for Regional TB Control Units is available at:
www.health.qld.gov.au/chrisp/tuberculosis/appointments.asp
Specialist Staff for
(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications;
(b) Use for postoperative nausea and vomiting (PONV)
Specialist Staff for
(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications;
(b) Use for postoperative nausea and vomiting (PONV)
Specialist Staff for use in children who cannot use any other forms of ondansetron.
Where medicines are used outside their TGA approved indications, patients should be made fully aware of the
status of the medicine and appropriate consent obtained
Specialist Staff for
(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications;
(b) For use in postoperative nausea and vomiting (PONV) (i) in adult patients not responsive to alternative oral
antiemetic therapy; and (ii) in children.
Page 3 of 6
ITEM
#
MEDICINE
13/T01
ONDANSETRON
TABLET 8mg
13/055
C
PARAAMINOSALICYLIC
ACID Sachet 4g
13/055
D
PROTHIONAMIDE
13/028
CINACALCET
TABLET 30mg,
60mg, 90mg
SODIUM
CHLORIDE
COMPOUND
(Ringers solution
lactated with
glucose) Powder
for reconstitution
– sachet (4) plus
bottle with
13/048
Tablet 250mg
DECISION &
DATE
EFFECTIVE
1 Oct LAM)
AMENDED
01-Sep-13
(to be
reflected in
1 Oct LAM)
AMENDED
01-Oct-13
AMENDED
01-Oct-13
RESTRICTION
Where medicines are used outside their TGA approved indications, patients should be made fully aware of the
status of the medicine and appropriate consent obtained.
Specialist Staff for patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications.
For treatment after approval by the Medical Advisor Tuberculosis, CHRISP and TB Control, Communicable
Diseases Unit or delegate OR Director Regional Tuberculosis Control Unit.
The Medical Advisor Tuberculosis, CHRISP and TB Control should be contacted for any multi-drug or extremely
drug resistant cases and can be contacted during business hours via (07) 3328 9755 or email at:
CHRISP_TB@health.qld.gov.au
Contact information for Regional TB Control Units is available at:
www.health.qld.gov.au/chrisp/tuberculosis/appointments.asp
For treatment after approval by the Medical Advisor Tuberculosis, CHRISP and TB Control, Communicable
Diseases Unit or delegate OR Director Regional Tuberculosis Control Unit.
The Medical Advisor Tuberculosis, CHRISP and TB Control should be contacted for any multi-drug or extremely
drug resistant cases and can be contacted during business hours via (07) 3328 9755 or email at:
CHRISP_TB@health.qld.gov.au
Contact information for Regional TB Control Units is available at:
www.health.qld.gov.au/chrisp/tuberculosis/appointments.asp
DEFERRED
DEFERRED
Page 4 of 6
ITEM
#
13/049
13/051
13/T03
MEDICINE
paediatric tip
(FLO Kids Sinus
Care®)
SODIUM
CHLORIDE
COMPOUND
(sterile, isotonic),
paediatric nasal
spray,15mL (FLO
Baby
VITAMIN, FAT
SOLUBLE
COMPOUND in
tocopherol PEG
suspension,
chewable tablet,
soft gel capsule,
paediatric liquid
60mL
ANIDULAFUNGIN
INJECTION
100mg
13/T01
GRANISETRON
INJ’N 1mg in 1mL
13/T01
ONDANSETRON
WAFER 4mg
DECISION &
DATE
EFFECTIVE
RESTRICTION
DEFERRED
DEFERRED
DELETED
01-Sep-13
(to be
reflected in
1 Oct LAM)
DELETED
01-Sep-13
(to be
reflected in 1
Oct LAM)
DELETED
01-Sep-13
(to be
reflected in 1
Oct LAM)
Page 5 of 6
ITEM
#
MEDICINE
13/T01
ONDANSETRON
WAFER 8mg
13/052
PROSTAGLANDIN
13/T02
F2 ALPHA
(CARBOPROST)
250microgram in
1mL
SIMVASTATIN
TABLET 80mg
13/057
IVABRADINE
TABLET 7.5mg
13/054
LIGNOCAINE
PATCH 5%
DECISION &
DATE
EFFECTIVE
DELETED
01-Sep-13
(to be
reflected in
1 Oct LAM)
DELETED
01-Oct-13
RESTRICTION
DELETED
01-Sep-13
(to be
reflected in
1 Oct LAM)
NOT ADDED
NOT ADDED
Page 6 of 6